Patterns of minimal residual disease after high dose therapy in myeloma - A comparison of allografting and autografting.

被引：0
|
作者：
Haynes, AP
Carter, GI
Owen, R
Davis, F
Byrne, J
Bybee, A
Samsom, D
Morgan, GJ
Russell, NH
机构：
[1] CITY HOSP NOTTINGHAM,DEPT HAEMATOL,NOTTINGHAM,ENGLAND
[2] LEEDS GEN INFIRM,LEEDS,W YORKSHIRE,ENGLAND
[3] HAMMERSMITH HOSP,LONDON,ENGLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：995 / 995
页数：1
相关论文
共 50 条
  • [41] COUNTERPOINT Should minimal residual disease negativity not bee the end point of myeloma therapy?
    Sonneveld, Pieter
    BLOOD ADVANCES, 2017, 1 (08) : 522 - 525
  • [42] DETECTION OF MINIMAL RESIDUAL DISEASE AFTER BMT FOR MYELOMA USING IMMUNOGLOBULIN GENE FINGERPRINTING
    BIRD, J
    SAMSON, D
    RUSSELL, N
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 : 14 - 14
  • [43] Individual molecular monitoring of minimal residual disease after autotransplantation in patients with multiple myeloma
    Zherebtsova, V.
    Surin, V.
    Savchenko, V.
    Mendeleeva, L.
    Pokrovskaya, O.
    Turina, N.
    Misurin, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S143 - S143
  • [44] Post-transplant consolidation chemotherapy to eliminate minimal residual disease in myeloma patients after high-dose melphalan and autotransplantation: Feasibility and tolerance.
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Bhagwati, N
    Saso, R
    Horton, C
    Singhal, S
    Mehta, J
    BLOOD, 1999, 94 (10) : 314B - 314B
  • [45] ERADICATION OF MINIMAL RESIDUAL DISEASE, ANALYZED BY PCR, AFTER DOUBLE HIGH-DOSE CHEMORADIOTHERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA
    BJORKSTRAND, B
    LJUNGMAN, P
    BIRD, JM
    SAMSON, D
    GAHRTON, G
    BLOOD, 1994, 84 (10) : A208 - A208
  • [46] The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma
    Davies, FE
    Forsyth, PD
    Rawstron, AC
    Owen, RG
    Pratt, G
    Evans, PAS
    Richards, SJ
    Drayson, M
    Smith, GM
    Selby, PJ
    Child, JA
    Morgan, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) : 814 - 819
  • [47] Molecular level of minimal residual disease in bone marrow before high-dose therapy and autologous stem cell transplantation is a prognostic parameter in patients with multiple myeloma
    Fenk, Roland
    Korthals, Mark
    Schnke, Nina
    Bruns, Ingmar
    Czibere, Akos
    Zohren, Fabian
    Safaian, Nancy
    Dienst, Ariane
    Ruf, Leilani
    Neumann, Frank
    Haas, Rainer
    Kronenwett, Ralf
    Kobbe, Guido
    BLOOD, 2007, 110 (11) : 448A - 448A
  • [48] The clinical significance of the monitoring minimal residual disease for maintanence therapy after autologous stem cells transplantation in patients with multiple myeloma
    Shamansky, S.
    Fedotova, I.
    Novoseltceva, L.
    Melkova, C.
    Pisarevskaya, O.
    Rukavitcin, O.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5597 - 5598
  • [49] Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy
    Kostopoulos, Ioannis V.
    Kastritis, Efstathios
    Papanota, Aristea-Maria
    Micheli, Paraskevi
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Fotiou, Despina
    Kanellias, Nikolaos
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Tsitsilonis, Ourania
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E185 - E186
  • [50] Peripheral blood progenitor cell mobilization and autografting following high-dose therapy in patients with multiple myeloma (MM)
    Goldschmidt, H
    Haas, R
    Hegenbart, U
    Wallmeier, M
    Hohaus, S
    Wannenmacher, M
    Hunstein, W
    BLOOD, 1996, 88 (10) : 512 - 512
12345